Anticoagulated patients
Warfarin, DOACs (dabigatran, rivaroxaban, apixaban), heparin, antiplatelets. When to hold, when not to hold, and how to achieve local hemostasis without systemic measures.
Anticoagulant therapy and bleeding risk
About 8% of adults over 65 take oral anticoagulants. Current ACC/AHA (2017) and ESC (2021) recommendations do NOT require holding therapy for most minor procedures (dentistry, dermatology, biopsies) — the thrombosis risk of holding outweighs the bleeding risk of continuing. Local hemostasis is the backbone of the protocol.
Drug classes and their characteristics
Warfarin (VKA)
Monitored by INR. Target range 2.0–3.0 for most indications. With INR in range, minor procedures are safe without holding. Reversal — vitamin K, FFP, PCC.
DOACs
Dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban. No monitoring needed. Half-life 8–14 h. For minor procedures the day-of dose can be skipped or continued at the physician's discretion.
Antiplatelets
Aspirin, clopidogrel, ticagrelor, prasugrel. Reduce platelet function for 7–10 days. Holding is rarely justified in CAD/stent patients — high thrombosis risk.
Heparin (LMWH/UFH)
Therapeutic LMWH doses (enoxaparin 1 mg/kg BID) are held 12–24 h before the procedure. UFH infusion is stopped 4 h prior. Reversal — protamine sulfate.
Hemostasis in anticoagulated patients
Pre-procedure assessment
INR for warfarin, last DOAC dose, antiplatelet dose. Bleeding risk by HAS-BLED, thrombosis risk by CHA2DS2-VASc.
First-line topical hemostat
BloodSTOP iX® on the bleeding source with 3–5 min compression. Enough for most patients — no need to hold therapy.
Tranexamic acid
5% solution mouthwash after a dental procedure (4 times a day for 5 days). Reduces delayed-bleeding risk in warfarin users.
Reversal in severe bleeding
Warfarin — vitamin K + PCC. Dabigatran — idarucizumab. Rivaroxaban/apixaban — andexanet alfa or PCC. Antiplatelets — platelet transfusion in life-threatening bleeding.
BloodSTOP iX®'s role
For anticoagulated patients BloodSTOP iX® is especially valuable because it works through a physical barrier and platelet activation at the application site — not through the coagulation system, which is inhibited in these patients. This avoids holding the drug and the associated thromboembolism risk in most cases. Especially effective in dental surgery, minor dermatologic surgery, and elderly epistaxis.
BloodSTOP iX 5×5 cm
Dentistry, dermatology, small procedures in DOAC/warfarin/antiplatelet patients.
BloodSTOP iX 10×5 cm
Epistaxis in elderly patients on warfarin or clopidogrel.
Clinical guidelines
ACC/AHA Perioperative Management of Antithrombotic Therapy
Doherty J.U. et al. · Journal of the American College of Cardiology · 2017
On requestHemostasis in patients on anticoagulants — modern approaches
Levy J.H. et al. · Annals of Surgery · 2021
On request
Further reading
More on the manufacturer's site
LifeScience Plus maintains a detailed topic page with clinical cases. Opens in a new tab.